Upadacitinib has recently been approved for treating Crohn's disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with difficult-to-treat CD being cared for at clinical centers across Italy.
Bezzio, C., Franchellucci, G., Savarino, E.v., Mastronardi, M., Caprioli, F.a., Bodini, G., et al. (2024). Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease. CROHN’S & COLITIS 360, 6(4), 1-5 [10.1093/crocol/otae060].
Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease
Calabrese E.;Ceccarelli L.Membro del Collaboration Group
;Cappello M.Membro del Collaboration Group
;
2024-10-01
Abstract
Upadacitinib has recently been approved for treating Crohn's disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with difficult-to-treat CD being cared for at clinical centers across Italy.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
bezzio c.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
380.72 kB
Formato
Adobe PDF
|
380.72 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
